Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $81.67 Consensus Target Price from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have been given a consensus rating of “Moderate Buy” by the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among analysts that have covered the stock in the last year is $81.6667.

ARWR has been the topic of a number of recent analyst reports. B. Riley Financial increased their target price on shares of Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Royal Bank Of Canada upped their price objective on shares of Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a research note on Thursday, December 11th. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 10th. Morgan Stanley boosted their target price on Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the company an “equal weight” rating in a report on Wednesday, January 7th. Finally, Chardan Capital upped their target price on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th.

Insider Buying and Selling

In other news, COO Patrick O’brien sold 49,493 shares of the stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $63.11, for a total value of $3,123,503.23. Following the completion of the sale, the chief operating officer directly owned 474,908 shares of the company’s stock, valued at approximately $29,971,443.88. This represents a 9.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Adeoye Y. Olukotun sold 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 19th. The stock was sold at an average price of $67.66, for a total transaction of $676,600.00. Following the transaction, the director owned 33,600 shares in the company, valued at approximately $2,273,376. This trade represents a 22.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 311,538 shares of company stock valued at $20,411,342 in the last 90 days. Company insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Tsfg LLC purchased a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at about $25,000. First Horizon Corp purchased a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter worth about $32,000. WPG Advisers LLC increased its position in Arrowhead Pharmaceuticals by 384.8% in the 4th quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 431 shares during the period. Hantz Financial Services Inc. raised its stake in Arrowhead Pharmaceuticals by 177.1% during the 4th quarter. Hantz Financial Services Inc. now owns 737 shares of the biotechnology company’s stock valued at $49,000 after acquiring an additional 471 shares during the last quarter. Finally, Elyxium Wealth LLC acquired a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth approximately $54,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Performance

Shares of ARWR opened at $57.37 on Thursday. The stock has a 50 day moving average price of $64.34 and a 200 day moving average price of $51.82. The company has a quick ratio of 3.38, a current ratio of 3.38 and a debt-to-equity ratio of 0.29. The company has a market capitalization of $8.03 billion, a price-to-earnings ratio of 37.50 and a beta of 1.23. Arrowhead Pharmaceuticals has a 52-week low of $9.57 and a 52-week high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last released its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million for the quarter, compared to analyst estimates of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The firm’s revenue for the quarter was up 10461.3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.39) EPS. Research analysts predict that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.